Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 24929235)

1.

No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.

Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM.

Clin Gastroenterol Hepatol. 2014 Dec;12(12):2106-12.e1. doi: 10.1016/j.cgh.2014.05.024. Epub 2014 Jun 11.

PMID:
24929235
2.

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E.

Gastroenterology. 2014 Apr;146(4):980-8. doi: 10.1053/j.gastro.2013.12.028. Epub 2013 Dec 22.

PMID:
24368224
3.

Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F.

J Hepatol. 2013 Oct;59(4):684-95. doi: 10.1016/j.jhep.2013.05.038. Epub 2013 Jun 3.

PMID:
23742912
4.

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.

Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K.

Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22.

PMID:
21374657
5.

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F.

Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20.

PMID:
20600025
6.

Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.

Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ.

World J Gastroenterol. 2015 Mar 7;21(9):2746-53. doi: 10.3748/wjg.v21.i9.2746.

7.

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD.

Hepatology. 2014 Feb;59(2):434-42.

PMID:
23939953
8.

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.

Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW.

Gut. 2011 Feb;60(2):247-54. doi: 10.1136/gut.2010.223206. Epub 2010 Oct 29.

PMID:
21036792
9.

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.

Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS.

Gut. 2015 Mar 23. pii: gutjnl-2014-308435. doi: 10.1136/gutjnl-2014-308435. [Epub ahead of print]

PMID:
25800784
10.

Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.

Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH.

World J Gastroenterol. 2012 Dec 21;18(47):6996-7002. doi: 10.3748/wjg.v18.i47.6996.

11.

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER.

Hepatology. 2011 Jan;53(1):62-72. doi: 10.1002/hep.23952. Epub 2010 Oct 27.

PMID:
21254162
12.

Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.

Alvarez-Uria G, Ratcliffe L, Vilar J.

HIV Med. 2009 May;10(5):269-73. doi: 10.1111/j.1468-1293.2008.00683.x. Epub 2009 Feb 5.

PMID:
19210695
13.

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.

van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T.

Hepatology. 2006 Aug;44(2):318-25.

PMID:
16871563
14.

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS.

Gut. 2015 Jan 16. pii: gutjnl-2014-308353. doi: 10.1136/gutjnl-2014-308353. [Epub ahead of print]

PMID:
25596179
15.

Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.

Childs K, Joshi D, Byrne R, Bruce M, Carey I, Agarwal K, Taylor C.

AIDS. 2013 Jun 1;27(9):1443-8. doi: 10.1097/QAD.0b013e32836011c2.

PMID:
23435302
16.

Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.

Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC.

Antimicrob Agents Chemother. 2008 Oct;52(10):3617-32. doi: 10.1128/AAC.00654-08. Epub 2008 Aug 1.

17.

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.

N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

18.

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.

Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ.

Antimicrob Agents Chemother. 2013 Jul;57(7):3369-74. doi: 10.1128/AAC.00587-13. Epub 2013 May 6.

19.

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.

Antivir Ther. 2004 Jun;9(3):353-63.

PMID:
15259898
20.

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.

van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T.

Hepatology. 2010 Jan;51(1):73-80. doi: 10.1002/hep.23246.

PMID:
19998272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk